Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy.
We report a patient with dysthyroid optic neuropathy refractory to steroids and orbital decompression treated with rapamycin, a fibroblast and T cell inhibitor. Symptoms, visual acuity, color plate testing, and visual fields improved. Aside from hypercholesterolemia, no complication related to this therapy was observed. By addressing the pathogenesis of thyroid eye disease, rapamycin may represent an alternative when standard treatments fail. Further investigation of rapamycin for treatment of dysthyroid orbitopathy is warranted.
Chang
Susie
S
Cole Eye Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Perry
Julian D
JD
Kosmorsky
Gregory S
GS
Braun
William E
WE
D049970:Graves Ophthalmopathy / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009408:Nerve Compression Syndromes / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009901:Optic Nerve Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D020123:Sirolimus / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D014792:Visual Acuity
D007166:Immunosuppressive Agents; D020123:Sirolimus